PTO/SB/64 (09-04)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN APPLICATION FOR PATENT ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)		Docket Number (Optional) TOMK0004	
First named inventor: Mohammad Reza MEHRABI			
Application No.:	Art Unit:		
Filed: January 10, 2005	Examiner:		
Title: USE OF ALPROSTADIL (PROSTAGLANDIN E1) FOR PRODUCING A MEDICAMENT FOR ANGIONEOGENESIS			
Attention: Office of Petitions Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 FAX (703) 872-9306			
NOTE: If information or assistance is needed in completing this form, please contact Petitions Information at (703) 305-9282.			
The above-identified application became abandoned for failure to file a timely and proper reply to a notice or action by the United States Patent and Trademark Office. The date of abandonment is the day after the expiration date of the period set for reply in the office notice or action plus an extensions of time actually obtained. APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION			
NOTE: A grantable petition requires the following items: (1) Petition fee; (2) Reply and/or issue fee; (3) Terminal disclaimer with disclaimer fee - required for all utility and plant applications filed before June 8, 1995; and for all design applications; and (4) Statement that the entire delay was unintentional.			
1.Petition fee Small entity-fee \$ (37 CFR 1.17(m)). Applicant claims small entity status. See 37 CFR 1.27. X Other than small entity – fee \$ (37 CFR 1.17(m))			
Reply and/or fee A. The reply and/or fee to the above-noted Office action in the form of(identify type of reply):			
has been filed previously on is enclosed herewith.	·		
B. The issue fee and publication fee (if applicable) of \$has been paid previously on is enclosed herewith.			
[Page 1 of 2]			

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mall Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

01/14/2005 GFREY1 00000149 lf you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/64 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee			
X Since this utility/plant application was filed on or after June 8, 1995, no terminal disclaimer is required.			
A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ for a small entity or \$ for other than a small entity) disclaiming the required period of time is enclosed herewith (see			
PTO/SB/63).			
filing of a grantable petition under 37 CFR 1.13 Trademark Office may require additional inform	uired reply from the due date for the required reply until the 7(b) was unintentional. [NOTE: The United States Patent and ation if there is a question as to whether either the der 37 CFR 1.137(b) was unintentional (MPEP 711.03(c),		
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
O, (///www	Deg. 04		
Signature	Date		
DR. MOHAMMAD M	EHRADI		
Typed or printed nam			
A-1230 VIENNA MOSE	TI GGASSE 8		
Address	Telephone Number		
AUSTRIA			
Address Enclosures: X Fee Payment			
Reply			
Terminal Disclaimer Form			
Additional sheets containing statements establishing unintentional delay			
Other:	*		
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]			
I hereby certify that this correspondence is being: Deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.			
Transmitted by facsimile on the date Office as (703) 872-9306.	e shown below to the United States Patent and Trademark		
Date	Signature		
Date	Signature		
	Typed or printed name of person signing certificate		
L			

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

Confirmation No.

Applicant:

Mohammad Reza

MEHRABI

Filed:

TC/A.U.

Examiner:

Docket No.

TOMK0004

Customer No.

25235

Communication (10).

Title: USE OF ALPROSTADIL

(PROSTAGLANDIN E1) FOR PRODUCING A MEDICAMENT FOR ANGIONEOGENESIS

DECLARATION OF MOHAMMAD REZA MEHRABI

Commissioner for Patents Alexandria, VA 22313-1450

Sir:

- I, Mohammed Reza MEHRABI, do declare as follows:
 - I am the applicant/sole inventor of PCT/AT00/00252 filed September 21, 2000, which claims priority of Austria Patent application No. A 1635/99 filed September 29, 1999, from which the present application is a U.S. national filing.
 - 2. It just came to my attention that March 29, 2002 was the deadline for filing a U.S. patent application based upon PCT/AT00/00252 and that a U.S. national filing was not undertaken by that date.
 - 3. Having just learned a national filing was not completed in the U.S. for PCT/AT00/00252 by March 29, 2002, I promptly authorized European patent counsel to engage U.S. patent counsel to undertake a U.S. national filing as promptly as possible, and do

hereby state that the failure to file such a U.S. patent application was at all times on and after March 29, 2002, unintentional.

4. I hereby declare that all statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true. I further declare I understand that willful false statements and the like made herein are punishable by fine or imprisonment, or both (18 U.S.C. § 1001) and may jeopardize the validity of the above-referenced application or any patent issuing thereon.

Respectfully submitted,

01/05/2005

December 2004

Mohammad Reza MEHRABI